These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 23224461)

  • 1. Olanzapine-induced neuroleptic malignant syndrome in a patient with probable dementia with Lewy bodies.
    Teng PR; Yeh CH; Lin CY; Lai TJ
    J Neuropsychiatry Clin Neurosci; 2012; 24(4):E1-2. PubMed ID: 23224461
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjunct treatment with levodopa in a patient with dementia with Lewy bodies, delusions and severe neuroleptic hypersensitivity syndrome.
    Majic T; Mell T; Heinz A; Rapp MA
    Int Psychogeriatr; 2010 Jun; 22(4):678-9. PubMed ID: 20199702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunct treatment with levodopa in a patient with dementia with Lewy bodies, delusions and severe neuroleptic hypersensitivity syndrome: some comments.
    McKeith I
    Int Psychogeriatr; 2010 Jun; 22(4):680. PubMed ID: 20170586
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrent spontaneous "neuroleptic malignant syndrome" in the absence of neuroleptic medication in probable dementia with Lewy bodies.
    Weber KE; Linker RA; Lorenz R; Muellges W; Naumann M; Reiners K; Classen J
    J Neurol; 2005 Sep; 252(9):1122-4. PubMed ID: 15765193
    [No Abstract]   [Full Text] [Related]  

  • 5. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia.
    Srivastava A; Borkar HA; Chandak S
    Psychiatry Clin Neurosci; 2009 Feb; 63(1):119-21. PubMed ID: 19067992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic malignant syndrome and catatonia in a patient with dementia.
    Singh D; Forlano R; Athey R
    Aust N Z J Psychiatry; 2008 Jun; 42(6):547-8. PubMed ID: 18494081
    [No Abstract]   [Full Text] [Related]  

  • 7. Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment.
    Oglodek E; Szota A; Araszkiewicz A
    Aust N Z J Psychiatry; 2013 Oct; 47(10):972. PubMed ID: 23630396
    [No Abstract]   [Full Text] [Related]  

  • 8. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case report.
    Kobayashi A; Kawanishi C; Matsumura T; Kato D; Furukawa R; Kishida I; Hirayasu Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1170-2. PubMed ID: 16682107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A Case of Neuroleptic Malignant Syndrome Associated with Undiagnosed Dementia with Lewy Bodies].
    Oka M; Komasawa N; Nishihara I; Fukuda M; Minami T
    Masui; 2015 Nov; 64(11):1190-2. PubMed ID: 26689073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Butyrophenone-induced neuroleptic malignant syndrome in Lewy body dementia: A cautionary tale.
    Seebaluck J; Colebatch JG; Chan BS
    Emerg Med Australas; 2023 Feb; 35(1):183-184. PubMed ID: 36316025
    [No Abstract]   [Full Text] [Related]  

  • 11. Olanzapine-associated neuroleptic malignant syndrome.
    Norgard NB; Stark JE
    Pharmacotherapy; 2006 Aug; 26(8):1180-2. PubMed ID: 16863495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome as part of an akinetic crisis associated with sepsis in a patient with Lewy body disease.
    Manabe S; Yanagi H; Ozawa H; Takagi A
    BMJ Case Rep; 2019 Feb; 12(2):. PubMed ID: 30824461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome.
    Mendhekar DN; Duggal HS
    J Neuropsychiatry Clin Neurosci; 2006; 18(4):552-3. PubMed ID: 17135384
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuroleptic malignant syndrome in an adolescent after brief exposure to olanzapine.
    Hanft A; Eggleston CF; Bourgeois JA
    J Child Adolesc Psychopharmacol; 2004; 14(3):481-7. PubMed ID: 15650507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine-associated neuroleptic malignant syndrome in a patient receiving concomitant rivastigmine therapy.
    Stevens DL; Lee MR; Padua Y
    Pharmacotherapy; 2008 Mar; 28(3):403-5. PubMed ID: 18294120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of head drop after discontinuation of olanzapine in a DLB patient.
    Aries MJ; Debruyne H; Engelborghs S; Le Bastard N; Somers N; Gorissen D; Pickut BA; De Deyn PP
    Mov Disord; 2008 Sep; 23(12):1760-2. PubMed ID: 18661562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroleptic malignant syndrome induced by donepezil.
    Matsumoto T; Kawanishi C; Isojima D; Iseki E; Kishida I; Kosaka K
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):101-3. PubMed ID: 14731314
    [No Abstract]   [Full Text] [Related]  

  • 18. Atypical (olanzapine) plus conventional (fluphenazine) neuroleptic treatment associated with the neuroleptic malignant syndrome.
    Tofler IT; Ahmed B
    J Clin Psychopharmacol; 2003 Dec; 23(6):672-4. PubMed ID: 14624203
    [No Abstract]   [Full Text] [Related]  

  • 19. Atypical neuroleptic malignant syndrome presenting as fever of unknown origin in the elderly.
    Hall RC; Appleby B; Hall RC
    South Med J; 2005 Jan; 98(1):114-7. PubMed ID: 15678646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms.
    Baskys A
    J Clin Psychiatry; 2004; 65 Suppl 11():16-22. PubMed ID: 15264967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.